Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

In an interview with conservative commentator Benny Johnson, the senator said he knew both would be considered conspiracy theorists.

a treatment for bipolar disorder and depression. Management said they now expect sales of $92 billion this year, up from a previous forecast of $91.3 billion. Johnson & Johnson’s cash flow.

The pregnant mother of two just wanted some relief for severe nausea. She was in disbelief when she was later admitted to a mental health unit.

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ... in MADRS at day 8 compared to Johnson & Johnson's pioneering ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March ...

Johnson made headlines in 2023 after revealing he’d undergone ... Yet despite his wealth and achievements, he was deeply unhappy, battling depression and suicidal ideation for the better part of a ...

The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...